LU93277I2 - Elotuzumab - Google Patents

Elotuzumab Download PDF

Info

Publication number
LU93277I2
LU93277I2 LU93277C LU93277C LU93277I2 LU 93277 I2 LU93277 I2 LU 93277I2 LU 93277 C LU93277 C LU 93277C LU 93277 C LU93277 C LU 93277C LU 93277 I2 LU93277 I2 LU 93277I2
Authority
LU
Luxembourg
Prior art keywords
elotuzumab
Prior art date
Application number
LU93277C
Other languages
English (en)
Original Assignee
Abbvie Biotherapeutics Inc
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38831279&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU93277(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Biotherapeutics Inc, Dana Farber Cancer Inst Inc filed Critical Abbvie Biotherapeutics Inc
Publication of LU93277I2 publication Critical patent/LU93277I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU93277C 2006-08-07 2016-10-24 Elotuzumab LU93277I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83618506P 2006-08-07 2006-08-07
US94426207P 2007-06-15 2007-06-15
PCT/US2007/075403 WO2008019378A1 (fr) 2006-08-07 2007-08-07 Méthodes de traitement du myélome multiple mettant en œuvre des polythérapies à base d'anticorps anti-cs1

Publications (1)

Publication Number Publication Date
LU93277I2 true LU93277I2 (fr) 2016-12-27

Family

ID=38831279

Family Applications (3)

Application Number Title Priority Date Filing Date
LU93276C LU93276I2 (fr) 2006-08-07 2016-10-24 Elotuzumab
LU93275C LU93275I2 (fr) 2006-08-07 2016-10-24 Elotuzumab
LU93277C LU93277I2 (fr) 2006-08-07 2016-10-24 Elotuzumab

Family Applications Before (2)

Application Number Title Priority Date Filing Date
LU93276C LU93276I2 (fr) 2006-08-07 2016-10-24 Elotuzumab
LU93275C LU93275I2 (fr) 2006-08-07 2016-10-24 Elotuzumab

Country Status (24)

Country Link
US (4) US8632772B2 (fr)
EP (5) EP2641601B8 (fr)
JP (1) JP5340935B2 (fr)
CN (1) CN101686971B (fr)
AU (1) AU2007281684C1 (fr)
BR (1) BRPI0716647A2 (fr)
CA (1) CA2660356C (fr)
CY (5) CY1116247T1 (fr)
DK (2) DK2641601T3 (fr)
ES (2) ES2535437T3 (fr)
HK (1) HK1129853A1 (fr)
HR (2) HRP20150449T1 (fr)
HU (4) HUE029027T2 (fr)
IL (2) IL196919A (fr)
LT (4) LT2641601T (fr)
LU (3) LU93276I2 (fr)
MX (1) MX2009001441A (fr)
NL (1) NL300840I2 (fr)
NO (1) NO346835B1 (fr)
NZ (1) NZ574978A (fr)
PL (2) PL2068874T3 (fr)
PT (2) PT2641601T (fr)
SI (2) SI2068874T1 (fr)
WO (1) WO2008019378A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2641601T (pt) 2006-08-07 2016-10-14 Dana Farber Cancer Inst Inc Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em huluc63 com bortezomib
EP2425849A3 (fr) * 2006-08-07 2012-05-09 Abbott Biotherapeutics Corp. Compositions et procédés d'utilisation d'anticorps anti-CS1 pour traiter plusieurs myélomes
JP2011523560A (ja) * 2008-06-02 2011-08-18 ダナ−ファーバー キャンサー インスティテュート インク． Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
US8563700B2 (en) * 2008-06-16 2013-10-22 Immunogen, Inc. Synergistic effects
AP2011005690A0 (en) * 2008-10-21 2011-06-30 Onyx Therapeutics Inc Combination therapy with peptide epoxyketones.
AU2010293383B2 (en) * 2009-09-10 2014-12-18 Kyowa Kirin Co., Ltd. Medicament including antibody composition specifically bound to human CC chemokine receptor 4 (CCR4)
US8841325B2 (en) * 2009-11-24 2014-09-23 Celgene Corporation Immunomodulatory compounds for the restoration of vitamin D sensitivity in vitamin D resistant tumor cells
CN102241773B (zh) * 2010-05-13 2014-05-14 四川大学 抗骨髓瘤细胞多克隆抗体及其制备方法
CN105377288B (zh) 2012-11-05 2019-11-15 达纳-法伯癌症研究所股份有限公司 Xbp1、cd138和cs1肽的组合物制备药物的用途
WO2015069785A1 (fr) * 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Combinaison d'anticorps anti-kir et d'anticorps anti-cs1 pour traiter un myélome multiple
WO2015069703A1 (fr) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Schémas posologiques immunothérapeutiques et combinaisons de ceux-ci
EP3783020A1 (fr) * 2013-11-21 2021-02-24 F. Hoffmann-La Roche AG Anticorps anti-alpha-synucleine et procédés d'utilisation
HRP20230265T1 (hr) * 2014-08-22 2023-04-14 Celgene Corporation Postupci liječenja multiplog mijeloma imunomodulatornim spojevima u kombinaciji s protutijelima
WO2016049022A1 (fr) * 2014-09-23 2016-03-31 Board Of Trustees Of Michigan State University Compositions et procédés de modulation d'une réponse immunitaire
WO2016054354A1 (fr) 2014-10-02 2016-04-07 Dana-Farber Cancer Institute, Inc. Compositions et méthodes pour le traitement de tumeurs malignes
CA2966005C (fr) 2014-10-31 2021-04-27 Abbvie Biotherapeutics Inc. Anticorps anti-cs1 et conjugues anticorps-medicament
WO2016073184A1 (fr) 2014-11-04 2016-05-12 Dana Farber Cancer Institute, Inc. Compositions et procédés pour le traitement d'un myélome multiple
MX2017007097A (es) * 2014-12-04 2017-09-05 Bristol Myers Squibb Co Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
CA2984464C (fr) * 2015-05-13 2023-10-10 Morphosys Ag Traitement pour le myelome multiple (mm)
BR112017027692A2 (pt) 2015-06-29 2018-10-09 Bristol Myers Squibb Co regimes de dosagem imunoterapêuticos compreendendo pomalidomida e um anticorpo anti-cs1 para tratamento do câncer
CN109432398A (zh) * 2016-03-13 2019-03-08 曹帅 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
US11124579B2 (en) 2017-03-29 2021-09-21 Agency For Science, Technology And Research Anti oligosaccharide antibody
AU2018372924A1 (en) * 2017-11-22 2020-04-23 Hillstream Biopharma Inc. Polymeric nanoparticles comprising bortezomib
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
CN115298549A (zh) 2019-11-05 2022-11-04 百时美施贵宝公司 M蛋白测定及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112969A (en) 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
EP0831860B1 (fr) 1995-05-25 2004-10-20 Baxter International Inc. Therapie cellulaire allogenique anticancereuse suivant une transplantation de cellules souches allogeniques
CA2752140A1 (fr) * 2002-05-17 2003-11-27 Celgene Corporation Methodes et compositions a base de 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione pour le traitement et la gestiondu cancer du rein
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US20090175866A1 (en) * 2004-11-04 2009-07-09 Avner Yayon Treatment of b-cell malignancies
PT2641601T (pt) 2006-08-07 2016-10-14 Dana Farber Cancer Inst Inc Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em huluc63 com bortezomib
EP2425849A3 (fr) * 2006-08-07 2012-05-09 Abbott Biotherapeutics Corp. Compositions et procédés d'utilisation d'anticorps anti-CS1 pour traiter plusieurs myélomes
US20080095768A1 (en) 2006-08-07 2008-04-24 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells

Also Published As

Publication number Publication date
IL243933A0 (en) 2016-04-21
NO20090968L (no) 2009-04-30
HK1129853A1 (en) 2009-12-11
HRP20150449T1 (en) 2015-06-05
ES2535437T3 (es) 2015-05-11
JP2010500371A (ja) 2010-01-07
NO346835B1 (no) 2023-01-23
HUS1600043I1 (hu) 2016-12-28
CY2016036I2 (el) 2017-07-12
EP2942057A1 (fr) 2015-11-11
US20170342150A1 (en) 2017-11-30
CN101686971B (zh) 2013-09-11
US20160137735A1 (en) 2016-05-19
CY1117992T1 (el) 2017-05-17
AU2007281684B2 (en) 2013-05-16
EP2068874B1 (fr) 2015-01-28
NZ574978A (en) 2012-08-31
PT2068874E (pt) 2015-05-21
DK2641601T3 (en) 2016-08-22
SI2068874T1 (sl) 2015-06-30
JP5340935B2 (ja) 2013-11-13
CY2016037I1 (el) 2017-07-12
AU2007281684A1 (en) 2008-02-14
LT2641601T (lt) 2016-10-10
LTPA2016030I1 (lt) 2016-11-10
CA2660356A1 (fr) 2008-02-14
NL300840I2 (fr) 2017-01-03
CY2016038I1 (el) 2017-07-12
EP2641601A1 (fr) 2013-09-25
PL2068874T3 (pl) 2015-06-30
HUS1600045I1 (hu) 2016-12-28
CN101686971A (zh) 2010-03-31
HRP20161284T1 (hr) 2016-12-16
EP2641600A1 (fr) 2013-09-25
EP2641601B1 (fr) 2016-07-06
CY2016036I1 (el) 2017-07-12
EP3115049A1 (fr) 2017-01-11
BRPI0716647A2 (pt) 2017-05-16
AU2007281684C1 (en) 2013-12-19
SI2641601T1 (sl) 2016-11-30
ES2589302T3 (es) 2016-11-11
LTPA2016031I1 (lt) 2016-11-10
US8632772B2 (en) 2014-01-21
EP2641601B8 (fr) 2016-09-21
IL196919A0 (en) 2009-11-18
CY1116247T1 (el) 2017-02-08
IL196919A (en) 2016-03-31
EP2068874A1 (fr) 2009-06-17
PT2641601T (pt) 2016-10-14
LU93276I2 (fr) 2016-12-27
US20140322201A1 (en) 2014-10-30
HUS1600044I1 (hu) 2016-12-28
LTC2068874I2 (lt) 2018-11-12
MX2009001441A (es) 2009-07-06
PL2641601T3 (pl) 2017-01-31
CA2660356C (fr) 2016-04-05
HUE029027T2 (en) 2017-01-30
US20080152646A1 (en) 2008-06-26
LU93275I2 (fr) 2016-12-27
WO2008019378A1 (fr) 2008-02-14
DK2068874T3 (da) 2015-04-27
LTPA2016029I1 (lt) 2016-11-10

Similar Documents

Publication Publication Date Title
LU93276I2 (fr) Elotuzumab
DE602006019782D1 (de) Kapselperforationsmodul
DE602007002544D1 (de) Nuancierungsmittel
DE602007008423D1 (de) Flüssigkeitshärtung
DE602007003893D1 (de) Kippambossanordnung
DE602007012130D1 (de) Modifizierte flavin-adenin-dinucleotid-abhängige glucose-dehydrogenase
DE602007009267D1 (de) Reifenaufblasverfahren
DE602007009650D1 (de) Spiroindolinonderivate
DE602007006947D1 (de) Pyridopyrimidinonderivate
DE602007000258D1 (de) Kassetteneinspannmechanismus
DE602006020192D1 (de) Riemenscheibenanorndung
DE602007009337D1 (de) Tastfeedbackvorrichtung
AT504580A3 (de) Scan-einrichtung
DE602007001280D1 (de) Getränkeextraktor
DE602007008400D1 (de) Kaliummonopersulfatlösungen
DE602006019150D1 (de) Riemenscheibenanorndung
ATE546437T1 (de) Aminomethyl-4-imidazole
DE502007000218D1 (de) nsetzungen
DE502007002453D1 (de) Kunstoffverdichtergehäuse
DE602007000501D1 (de) Breitbandrichtkoppler
DE602007004080D1 (de) Tintenstrahlaufnehmer
DE602007007460D1 (de) Sehkrafttestsystem
DE602006016174D1 (de) Blisterverpackungsverfahren
DE502007000361D1 (de) Stanznieteinheit
DE502007001629D1 (de) Rfahren